NCT02862691

Brief Summary

The goal of this study is to compare the speed and adequacy of pain relief in Emergency Department patients with a toothache after an oral analgesic or a local anesthetic administered as a nerve block or by local infiltration.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Aug 2016

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2016

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

August 8, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 11, 2016

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

April 25, 2018

Status Verified

April 1, 2018

Enrollment Period

1 year

First QC Date

August 8, 2016

Last Update Submit

April 23, 2018

Conditions

Keywords

toothache

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with significant pain relief at the end of the study period

    Patients whose pain is reduced from severe (7-10) to mild (0-3) will be considered as having a meaningful reduction in pain.

    60 minutes

Secondary Outcomes (2)

  • Absolute change in pain severity

    60 minutes

  • The time to a 50% reduction in pain severity

    60 minutes

Study Arms (2)

Oral analgesic

ACTIVE COMPARATOR

2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once

Drug: Acetaminophen/Oxycodone (Oral analgesic)

Injectable local anesthetic

EXPERIMENTAL

local injection or nerve block with bupivicaine 0.5%

Drug: Bupivicaine (Injectable local anesthetic)

Interventions

2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once

Also known as: Acetaminophen/Oxycodone
Oral analgesic

local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth

Also known as: Bupivicaine
Injectable local anesthetic

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who present to the ED with a chief complaint of toothache, and a pain intensity rating of at least a 7 on an 11 item verbal numeric scale (from 0 or no pain to 10 or worst imaginable pain) will be eligible for enrollment.
  • Patient should have the capacity to provide informed consent.

You may not qualify if:

  • Patients presenting with a toothache due to trauma or post-operative procedure will be excluded as well as those requiring drainage of a dental abscess.
  • Patients who have any contraindications to the medications used in the study (allergy, history of GI bleeding, etc.).
  • Patients who cannot remain in the ED for at least 1 hour after study drug administration or do not have a ride home (if receiving Percocet) will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stony Brook University Hospital

Stony Brook, New York, 11794, United States

Location

MeSH Terms

Conditions

Toothache

Interventions

AcetaminophenOxycodoneAnalgesicsoxycodone-acetaminophen

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic DiseasesFacial PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsSensory System AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesCentral Nervous System AgentsTherapeutic Uses

Study Officials

  • Adam J Singer, MD

    Stony Brook University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice Chairman of Reserach

Study Record Dates

First Submitted

August 8, 2016

First Posted

August 11, 2016

Study Start

August 1, 2016

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

April 25, 2018

Record last verified: 2018-04

Data Sharing

IPD Sharing
Will share

Locations